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The urotensin II (UII) gene family consists of four paralogous genes called UII, UII-related
peptide (URP), URP1 and URP2. UII and URP peptides exhibit the same cyclic
hexapeptide core sequence (CFWKYC) while the N- and C-terminal regions are variable.
UII, URP1, and URP2 mRNAs are differentially expressed within the central nervous
system of teleost fishes, suggesting that they may exert distinct functions. Although
the cardiovascular, ventilatory and locomotor effects of UII have been described
in teleosts, much less is known regarding the physiological actions of URPs. The
goal of the present study was to compare the central and peripheral actions of
picomolar doses (5–500pmol) of trout UII, URP1, and URP2 on cardio-ventilatory
variables and locomotor activity in the unanesthetized trout. Compared to vehicle,
intracerebroventricular injection of UII, URP1 and URP2 evoked a gradual increase in
total ventilation (VTOT) reaching statistical significance for doses of 50 and 500pmol of
UII and URP1 but for only 500 pmol of URP2. In addition, UII, URP1 and URP2 provoked
an elevation of dorsal aortic blood pressure (PDA) accompanied with tachycardia. All
peptides caused an increase in locomotor activity (ACT), at a threshold dose of 5 pmol
for UII and URP1, and 50pmol for URP2. After intra-arterial (IA) injection, and in
contrast to their central effects, only the highest dose of UII and URP1 significantly
elevated VTOT and ACT. UII produced a dose-dependent hypertensive effect with
concomitant bradycardia while URP1 increased PDA and heart rate after injection
of only the highest dose of peptide. URP2 did not evoke any cardio-ventilatory or
locomotor effect after IA injection. Collectively, these findings support the hypothesis that
endogenous UII, URP1 and URP2 in the trout brain may act as neurotransmitters and/or
neuromodulators acting synergistically or differentially to control the cardio-respiratory
and locomotor systems. In the periphery, the only physiological actions of these peptides
might be those related to the well-known cardiovascular regulatory actions of UII. It
remains to determine whether the observed divergent physiological effects of UII and
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URPs are due to differential interaction with the UT receptor or binding to distinct UT
subtypes.
Keywords: urotensin II, urotensin II-related peptides, ventilatory variables, heart rate, blood pressure, locomotor
activity, brain, trout
Introduction
Urotensin II (UII) is a cyclic neuropeptide that was originally
isolated and purified from the caudal neurosecretory system of
the teleost fish Gillichthys mirabilis (longjaw mudsucker) on the
basis of its smoothmuscle-stimulating activity (Bern and Lederis,
1969; Pearson et al., 1980). Recently, it has been demonstrated
that UII belongs to a family of structurally related peptides that
include UII and UII-related peptides (URPs) called URP, URP1,
and URP2 (Lihrmann et al., 2013). UII, URP, URP1, and URP2
exhibit the same cyclic hexapeptide core sequence (CFWKYC)
while the N- and C-terminal regions are variable (Conlon, 2008;
Lihrmann et al., 2013). In the teleost lineage, all four paralog
genes are present but only two of them, UII and URP, are found
in tetrapods (Quan et al., 2012; Tostivint et al., 2013). In mam-
mals, UII and URP genes are mostly expressed in cholinergic
neurons of the brainstem and spinal cord but variable levels of
expression occur in most brainstem nuclei (Vaudry et al., 2015)
suggesting that the peptides may exert distinct biological func-
tions. UII and URP mRNAs are also differentially expressed in
peripheral tissues, including notably the cardiovascular, renal and
endocrine systems (Sugo et al., 2003; Dubessy et al., 2008; Vaudry
et al., 2015). UII and URP both activate the UT receptor with
the same potency (Sugo et al., 2003) but the two peptides may
exert differential modulatory effects due to recruitment of differ-
ent intracellular signaling pathways (Vaudry et al., 2010). The UT
receptor is present in several areas of the brain and spinal cord
but also in various peripheral organs including the cardiovascu-
lar system, endocrine tissues and kidney (Vaudry et al., 2015). UII
exerts a large array of biological effects including regulation of
various behaviors, motor and neuroendocrine activities, as well
as central and peripheral control of blood pressure and heart
rate but much less is known about the biological actions of URPs
(Vaudry et al., 2010, 2015). In fish, UII, URPs and the UT recep-
tor are also present in the brain and spinal cord. Pioneer studies
have demonstrated that UII-like immunoreactivity is primarily
found in cerebrospinal fluid (CSF)-contacting neurons located
within the ventral ependyma lining the central canal along the
entire length of the spinal cord and the medulla oblongata (Yulis
and Lederis, 1986, 1988). These CSF-contacting neurons con-
taining UII-like immunorecativity project their axons toward the
external surface of the spinal cord and ascending fibers inner-
vate various regions of the brain (Yulis and Lederis, 1986, 1988).
UII has been purified and characterized from extracts of the
brains of an elasmobranch, the skate Raja rhina, and a teleost,
Abbreviations: ACT, locomotor activity; a.u., arbitrary unit; CNS, central ner-
vous system; ECG, electrocardiographic; fH, heart rate; fV, ventilatory rate; IA,
intra-arterial; ICV, intracerebroventricular; PDA, dorsal aortic blood pressure; UII,
urotensin II; URP, urotensin II-related peptide; URP1, urotensin II-related peptide
1; URP2, urotensin II-related peptide 2; VAMP, ventilatory amplitude; VTOT, total
ventilation.
the rainbow trout Oncorhynchus mykiss (Waugh and Conlon,
1993). The expression of UII mRNA in fish brain has been con-
firmed by RT-PCR in the European flounder Platichthys flesus
(Lu et al., 2006), in the zebrafish Danio rerio (Parmentier et al.,
2008) and in the orange-spotted grouper Epinephelus coioides
(Sun et al., 2014). Extensive studies on the differential expres-
sion of URP, URP1 and URP2 in the central nervous system
(CNS) have been conducted in the Japanese eel Anguilla japon-
ica (Nobata et al., 2011) and in the zebrafish (Parmentier et al.,
2011; Quan et al., 2015). In zebrafish, URP mRNA is present in
motoneurons (cited in Quan et al., 2015). In both species, URP1
is mainly expressed in motoneurons of the medulla oblongata.
In zebrafish, URP2 mRNA is found in cells located along the
ventral edge of the fourth ventricle, probably in CSF-contacting
neurons, and in the spinal cord, URP1 and URP2 mRNAs co-
localize in same cells that are also CSF-contacting neurons (Quan
et al., 2015). In the flounder (Lu et al., 2006), the killifish Fundulus
heteroclitus (Evans et al., 2011) and the orange-spotted grouper
(Sun et al., 2014), the UT receptor is strongly expressed in the
caudal neurosecretory system, the CNS (brain and spinal cord)
but also in various peripheral tissues including the heart, gill, kid-
ney and ovary. UII is known to be involved in osmoregulation in
fish (Marshall and Bern, 1979; Lu et al., 2006; Evans et al., 2011)
and a few studies have examined the cardiovascular effects of UII
and URP1 in teleosts. In the rainbow trout, centrally adminis-
tered UII evokes an increase in dorsal aortic blood pressure (PDA)
with variable action on the heart (Le Mével et al., 1996), while
intra-arterial (IA) injection of UII provokes a dose-dependent
elevation in PDA with a concomitant bradycardia (Le Mével et al.,
1996). In the Japanese eel, the cardiovascular effects of centrally
and peripherally injected UII and URP1 are quite similar. Both
peptides preferentially elevate blood pressure in the ventral aorta
than in the dorsal aorta and evoke tachycardia (Nobata et al.,
2011). In addition, in the rainbow trout, central injection of UII
produces a hyperventilatory response and a long-lasting increase
in locomotor activity (Lancien et al., 2004). Nonetheless, due to
the relatively recent discovery of UPRs, nothing is known about
the potential actions of URP1 on ventilatory and locomotor func-
tions and those of URP2 on cardio-ventilatory and locomotor
functions. The differential although similar expression of UII,
URP1, and URP2 in the CNS of teleosts suggests that these pep-
tides may have synergistic or divergent biological effects. It is
thus important to determine the in vivo integrative actions of
these peptides on physiological functions and behavior in the
same animal. Therefore, the main goal of the present study was
to analyze the central effects of trout UII, URP1, and URP2 on
ventilatory and cardiovascular functions and on locomotor activ-
ity in our established trout model. To this end, we have ana-
lyzed the effects of intracerebroventricular (ICV) administration
of synthetic replicates of these peptides on ventilatory amplitude
(VAMP), ventilatory frequency (fV), total ventilation (VTOT), PDA,
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heart rate (fH), and locomotor activity (ACT). Additionally, the
central actions of the peptides were also compared with their
effects after IA injection.
Material and Methods
Peptides and Chemicals
The primary sequence of the urotensin peptides examined in this
study is shown in Table 1. Trout UII, URP1, and URP2 (Waugh
and Conlon, 1993; Tostivint et al., 2013) were synthesized as pre-
viously described (Chatenet et al., 2004; Lancien et al., 2004).
The peptides were dissolved in Ringer’s solution (vehicle) and
stored in stock solutions at −25◦C. Immediately before use, UII,
URP1, or URP2 were diluted to the desired concentration with
Ringer’s solution. The composition of the Ringer’s solution was
(inmM): NaCl 124, KCl 3, CaCl2 0.75,MgSO4 1.30, KH2PO41.24,
NaHCO3 12, glucose 10 (pH 7.8). All solutions were sterilized by
filtration through 0.22µm filters (Millipore, Molsheim, France)
before injection.
Animals
Adult rainbow trout Oncorhynchus mykiss (247 ± 24 g body wt,
mean ± SEM, n = 95) of both sexes were purchased locally and
transferred in a well-oxygenated and thermostatically controlled
water tank to the laboratory. All fish were kept in a 1000-liter tank
containing circulating dechlorinated and aerated tap water (11–
12◦C), under a standard photoperiod (lights on 09:00–20:00).
The fish were allowed at least 3 weeks to acclimate under these
conditions before the experiments were started. Experimental
protocols were approved by the Regional Ethics Committee in
Animal Experiments of Brittany, France.
Experimental Procedures
All surgical procedures were made under tricaine methane-
sulfonate (3-aminobenzoic acid ethyl ester methanesulfonate;
60mg/L in tap water buffered with NaHCO3 to pH 7.3–7.5)
anesthesia. The techniques used for placement of the electrocar-
diographic (ECG) electrodes, placement of the buccal catheter,
cannulation of the dorsal aorta and insertion of the ICVmicrogu-
ide have previously been described in detail (LeMével et al., 1993;
Lancien et al., 2004). Briefly, two ECG AgCl electrodes (Comepa,
Bagnolet, France) were subcutaneously implanted ventrally and
TABLE 1 | Amino-acid sequence of trout urotensin II (Waugh and Conlon,
1993) and teleost URP1 and URP2 (Tostivint et al., 2013) examined for their
cardio-ventilatory effects and locomotor activity following central and
peripheral injection in the unanesthetized rainbow trout Oncorhynchus
mykiss.
Urotensin II Amino-acid sequence
peptides
UII H-Gly-Gly-Asn-Ser-Glu-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH
URP1 H-Ala-Cys-Phe-Trp-Lys-Tyr-Cys-Val-Thr-Asn-OH
URP2 H-Val-Cys-Phe-Trp-Lys-Tyr-Cys-Ser-Gln-Asn-OH
The conserved cyclic hexapeptide core sequence (Cys-Phe-Trp-Lys-Tyr-Cys or CFWKYC)
of each peptide is in bold characters.
longitudinally at the level of the pectoral fins. The incision was
sutured across the electrodes and the leads were sutured to the
skin. The dorsal aorta was cannulated with a PE-50 catheter (Clay
Adams, Le Pont De Claix, France). A flared cannula (PE-160)
was inserted into a hole drilled between the nares such that its
flared end was resting against the roof of the mouth. This cannula
was used to record any changes in buccal ventilatory pressure.
The absence of a neocortex in fish allows the accurate place-
ment of the ICV microguide under stereomicroscopic guidance.
A 25-gauge needle fitted with a PE-10 polyethylene catheter was
inserted between the two habenular ganglia and descended into
the third ventricle until its tip lay between the two preoptic nuclei
(Le Mével et al., 2009). An obturator was placed at the end of
the PE-10 tubing and the cranial surface was covered with hemo-
static tissue followed by light quick-curing resin. After surgery,
the animals were force-ventilated with dechlorinated tap water
until recovery of opercular movements and transferred to a 6-
liter blackened chamber supplied with dechlorinated and aerated
tap water (10–11◦C) that was both re-circulating and through-
flowing. Oxygen partial pressure within the water tank (PwO2)
and pH were continuously recorded and maintained at constant
levels (PwO2 = 20 kPa; pH = 7.4–7.6). A small horizontal aper-
ture was made along the upper edge of the chamber in order to
connect the ECG leads to an amplifier and to connect the dorsal
aorta and the buccal cannula to pressure transducers. This aper-
ture also permitted ICV and IA injections of peptides without
disturbing the animals.
Trout were allowed to recover from surgery and to become
accustomed to their new environment for 48–72 h. Each day,
the general condition of the animals was assessed by observing
their behavior, checking the ventilatory and the cardiovascular
variables, and measuring their hematocrit. Animals that did not
appear healthy, according to the range of values detailed in our
previous studies, were discarded. After stable VAMP, fV, PDA, and
fH were maintained for at least 90min, parameters were recorded
for 30min without any manipulation in control experiments. To
minimize the use of experimental animals, some trout received
both ICV and IA injections. In this later case, the delay between
the two injections was 1 day, and the order of the injections was
randomized among animals. No single fish was studied for more
than 2 days and control experiments revealed that there was no
significant change in performance over this period.
Intracerebroventricular Administration of
Peptides
The injector was introduced within the ICV guide prior to the
beginning of a recording session which lasted 30min. All injec-
tions were made at the fifth minute of the test but the injector was
left in place for a further 5min to allow for complete diffusion
of the agent and to minimize the spread of substances upwards
in the cannula tract. The fish received first an ICV injection of
vehicle (0.5µl) and 30min later, an ICV injection of UII, URP1,
or URP2 (5, 50, and 500 pmol in 0.5µl). The rationale for using
these doses was that they were in the same range as those pre-
viously used for studies on the cardiovascular effects of UII in
trout and for comparison of effects between peptides (Le Mével
et al., 1996, 2012). Previous control experiments using two ICV
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injections 30min apart have shown no time-dependent changes
in the measured variables using this protocol (Le Mével et al.,
2009). The animals received no more than two ICV injections of
peptide per day with a delay of at least 5 h between the injections.
Intra-Arterial Administration of Peptides
Five minutes after the beginning of the recording session, 50µl
of vehicle, UII, URP1, or URP2 at doses of 5, 50, and 500 pmol
was injected through the dorsal aorta and immediately flushed
by 150µl of vehicle.
Data Acquisition and Analysis of
Cardio-Ventilatory Variables and Motor Activity
The ECG electrodes were connected to a differential ampli-
fier (band pass: 5–50Hz; Bioelectric amplifier, Gould & Nicolet,
Courtaboeuf, France) and a stainless steel bar was immersed in
the water of the tank to act as a reference electrode. The aortic
cannula and the buccal catheter were connected to P23XL pres-
sure transducers (band pass: 0–15Hz; Gould & Nicolet). These
pressure transducers were calibrated each day using a static water
column. At the beginning of the experiments, the zero-buccal
pressure level was set electronically. The output signals from the
devices were digitalized at 1000Hz and visualized on the screen
of a PC using PowerLab 4/30 data acquisition system (ADIn-
struments, Oxford, England) and LabChart Pro software (v.7.0;
ADInstruments, Oxford, England) during the 30-min record-
ing period and the data were stored on a disk. The time-series
related to the ventilatory, the pulsatile PDA and the ECG signals
were then processed off-line with custom-made programs writ-
ten in LabView 6.1 (Laboratory Virtual Instrument Engineering
Workbench, National Instruments, Austin, USA). Motor activity,
ventilatory and cardiovascular variables were calculated as pre-
viously described (Lancien et al., 2004; Le Mével et al., 2007).
Motor activity was detected as artifacts on the ventilatory sig-
nal (Lancien et al., 2004) and the total duration of locomotor
activity (ACT, in seconds) was determined from ventilatory signal
(Lancien et al., 2004). Thereafter, segments free of any movement
artifacts on the ventilatory signal were selected and fV (breaths
min−1) and VAMP (arbitrary units, a.u.) were determined. The fV
was calculated from the first harmonic of the power spectrum of
the ventilatory signal using the fast Fourier transformation.VAMP
was calculated from the difference between the maximal abduc-
tion phase and the maximal adduction phase for each ventilatory
cycle. Spontaneous coughings, which correspond to rapid and
robust changes in the abduction/adduction phases of the venti-
latory cycle, were excluded from this analysis. The net effect of
the changes in fV and VAMP on ventilation was estimated accord-
ing to the formula VTOT = fV × VAMP, where VTOT (a.u.)is
total ventilation. Mean PDA (kPa) was calculated from the pul-
satile PDA as the arithmetic mean between systolic blood pressure
and diastolic blood pressure, and the fH (beats min
−1) was deter-
mined from the ECG signal. All calculations for mean fV, VAMP,
VTOT, PDA, fH, and ACT were made for the pre-injection period
(0–5min) and for five post-injection periods of 5min for each
trout. To reduce the amount of data, only the maximal effects
of the various treatments in the above parameters were analyzed
and the results were averaged for trout subjected to the same
protocol. One-Way ANOVA analysis of baseline values of fV,
VAMP, VTOT, PDA, fH, and ACT during the pre-injection period
revealed that there was no statistical difference between groups
prior ICV or IA injection of vehicle or the various peptides (not
shown).
Statistical Analysis
Data are expressed asmeans+ SEM (standard error of themean).
The data were analyzed byOne-WayANOVA test followed by the
multiple comparison tests of Dunnett or Tukey. The criterion for
statistical difference between groups was P < 0.05. The statistical
tests were performed using GraphPad Prism 5.0 (GraphPad, San
Diego, USA).
Results
Ventilatory, Cardiovascular and Locomotor
Activity Responses to Central UII, URP1, and
URP2
The effects of ICV injections of vehicle, UII, URP1, and URP2 on
ventilatory and cardiovascular variables, and on locomotor activ-
ity are summarized in Figures 1–3, respectively. Compared with
ICV injection of vehicle, all peptides evoked quite similar increase
in VAMP (Figures 1A, 2A, 3A) and fV (Figures 1B,2B,3B). How-
ever, the threshold dose of UII inducing a significant effect on
VAMP was only 5 pmol while a 10-fold higher dose was required
for URP1 and URP2. All peptides provoked an elevation of fV
for a threshold dose of 50 pmol with minor differences between
peptides at the higher dose (Figures 1B,2B,3B). The net effect
of the ICV administration of the peptides was a hyperventi-
latory response involving a gradual and significant increase in
VTOT for doses of 50 and 500 pmol of UII and URP1 but for
only 500 pmol of URP2 (Figures 1C,2C,3C). In addition, UII,
URP1, and URP2 provoked a non-dose-dependent increase in
PDA (Figures 1D,2D,3D). However, the threshold dose for this
effect was only 5 pmol for UII and URP1 (Figures 1D, 2D) but
500 pmol for URP2 (Figure 3D). During this hypertensive effect
of the peptides, there was no bradycardia but instead, a significant
tachycardia occurred at the 50 and 500 pmol doses for most of the
peptides (Figures 1F,2F,3F). UII, URP1, and URP2 also caused a
potent increase in ACT for a threshold dose of 5 pmol for UII and
URP1 but 50 pmol for URP2.
Ventilatory, Cardiovascular and Locomotor
Activity Responses to Peripheral UII, URP1, and
URP2
Figures 4–6 depict the results obtained after IA administra-
tion of the different peptides on ventilatory and cardiovascu-
lar variables and on motor activity. In contrast to their central
effects, only the highest dose of UII and URP1 (500 pmol)
significantly elevated VAMP and the net effect of these pep-
tides was a hyperventilatory response since VTOT significantly
increased (Figures 4C,5C). Contrary to its ICV effects, IA injec-
tion of UII produced a significant dose-dependent increase in
PDA (Figure 4D) accompanied with a fH decrease, a bradycardia
statistically significant for the 5 and 50 pmol doses of peptide
(Figure 4E). Only the highest dose of URP1 (500 pmol) provoked
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FIGURE 1 | Histograms showing the maximal effects of ICV injection of
0.5µl of vehicle (n = 34), 5 pmol UII (n = 11), 50 pmol UII (n = 14) and
500pmol UII (n = 12) on ventilatory amplitude (VAMP, A), ventilatory
frequency (fV, B), total ventilation (VTOT, C), dorsal aortic blood
pressure (PDA, D), heart rate (fH, E), and motor activity (ACT, F).
*P < 0.05 vs. vehicle injection.
an elevation in PDA accompagnied by a significant tachycar-
dia (Figures 5D,E). IA injection of the highest dose of UII
and URP1 caused an increase in ACT (Figures 4F,5F). Periph-
eral administration of URP2 at any dose did not produce any
effect on the cardio-ventilatory variables and locomotor activity
(Figures 6A–F).
Discussion
This is the first functional study evaluating the integrative effects
of UII, URP1, and URP2 on physiological variables including
ventilation, blood pressure and locomotor activity in fish. The
most important outcome of this study is that ICV or IA admin-
istration of picomolar doses of these peptides exert both com-
mon and specific biological activities depending on the route of
administration. The demonstration that ICV injection of UII and
URPs evoked a stimulatory action on ventilation, cardiovascu-
lar variables and locomotion for doses that did not produce any
effect or evoked differential action after peripheral administra-
tion, supports the assumption that following ICV injection, cen-
tral neuronal sites are involved in the action of the peptides. In
addition, after IA injection, the exclusive effect of low picomolar
doses of UII on PDA and fH, confirms that this peptide may act
also to peripheral sites.
FIGURE 2 | Histograms showing the maximal effects of ICV injection of
0.5µl vehicle (n = 31), 5 pmol URP1 (n = 11), 50 pmol URP1 (n = 12) and
500pmol URP1 (n = 10) on ventilatory amplitude (VAMP, A), ventilatory
frequency (fV, B), total ventilation (VTOT, C), dorsal aortic blood
pressure (PDA, D), heart rate (fH, E), and motor activity (ACT, F).
*P < 0.05 vs. vehicle injection.
Ventilatory, Cardiovascular and Locomotor
Actions of Centrally Administered UII, URP1, and
URP2
The central actions of UII, URP1, and URP2 on cardio-
ventilatory and motor functions may be compared to those
reported in previous studies conducted with UII or URP1 in fish
or in other vertebrates species. The present results on UII are
consistent with our previous data demonstrating that, in trout,
UII administered through the ICV route causes a non-dose-
dependent elevation of PDA without bradycardia (Le Mével et al.,
1996). In the eel, central administration of UII and URP1 prefer-
entially elevates blood pressure of the branchial circulation higher
than that of the systemic circulation (Nobata et al., 2011). Conse-
quently, the hypertensive effect of eel UII on ventral aortic blood
pressure (PVA) is significant for doses higher than 0.15 nmol while
doses higher than 0.5 nmol are required to increase PDA. URP1
(0.3–0.5 nmol) provokes a significant dose-dependent increase in
PVA, but does not affect PDA at any dose(Nobata et al., 2011).
The effect of URP1 was longer lasting than that of UII and
the two peptides evoked tachycardia (Nobata et al., 2011). The
absence of bradycardia in response to an increase in blood pres-
sure following ICV injection of UII and URP1 in trout and eel,
and URP2 in trout suggests that the cardio-inhibitory barore-
ceptor reflex is altered following central injection of these pep-
tides. In normotensive and hypertensive unanesthetized rats (Lin
et al., 2003a,b) and in unanesthetized sheep (Watson and May,
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FIGURE 3 | Histograms showing the maximal effects of ICV injection of
0.5µl vehicle (n = 25), 5 pmol URP2 (n = 9), 50 pmol URP2 (n = 12) and
500pmol URP2 (n = 9) on ventilatory amplitude (VAMP, A), ventilatory
frequency (fV, B), total ventilation (VTOT, C), dorsal aortic blood
pressure (PDA, D), heart rate (fH, E), and motor activity (ACT, F).
*P < 0.05 vs. vehicle injection.
2004), ICV administration of UII causes pressor and tachycardic
responses through activation of the sympathetic system indicat-
ing that, in these species, also the cardiac baroreflex response
is impaired. Studies conducted on unanesthetized sheep to test
this hypothesis demonstrated that, after ICV infusion of UII
(0.2 nmol/kg for 1 h), the cardiac baroreflex response is effec-
tively blunted since no changes occur in the cardiac sympathetic
nerve activity in spite of an increase in blood pressure (Hood
et al., 2005). In rats, the central cardiovascular action of UII is
site-dependent and local administration of UII in discrete brain
nuclei produces differential cardiovascular responses (Lu et al.,
2002). To our knowledge, the central action of URP in mammals
has never been explored.
We have previously demonstrated that, in addition to its
central cardiovascular effects, UII produces a hyperventilatory
response and a stimulatory effect on locomotion (Lancien et al.,
2004, 2005). In the present study, UII-induced hyperventilation
was mimicked by URP1 and to a lesser extent by URP2. Fur-
thermore, at the low dose of 5 pmol, UII, URP1 but not URP2
provoked an increase in locomotion. Nonetheless, at this pico-
mole dose, UII and URP1 did not induced any change in VTOT.
These observations suggest that UII and URP1 act preferentially
on central neuronal networks controlling locomotion than ven-
tilation. This stimulatory effect of UII on locomotor activity in
fish is in accord with results obtained in rats (Gartlon et al., 2001)
and mice (Do-Rego et al., 2005) showing that ICV injection of
FIGURE 4 | Histograms showing the maximal effects of IA injection of
50µl vehicle (n = 29), 5 pmol UII (n = 10), 50 pmol UII (n = 16) and
500pmol UII (n = 7) on ventilatory amplitude (VAMP, A), ventilatory
frequency (fV, B), total ventilation (VTOT, C), dorsal aortic blood
pressure (PDA, D), heart rate (fH, E), and motor activity (ACT, F).
*P < 0.05 vs. vehicle injection.
human UII (hURP, ACFWKYCV) and mouse UII, respectively,
elicit motor activity in a familiar environment. It should be noted,
however, that the threshold doses eliciting locomotor effects in
rats and mice are in the nanomole range. Because UII and URPs
induced a marked increased in locomotor activity in trout, we
cannot exclude that the changes observed in cardio-ventilatory
parameters may be secondary effects of the peptides. Finally, in
our study and after ICV injection, a trend in the potency order
of UII, URP1, and URP2 emerged being UII ≥ URP1 > URP2
notably for the hyperventilatory, hypertensive and locomotor
actions of these peptides.
The receptor site(s) and the multisynaptic pathways involved
in initiating cardio-ventilatory and locomotor responses after
UII, URP1, and URP2 injection within the brain are matter of
speculation and require further studies. Nevertheless, as previ-
ously mentioned for the central actions of other neuropeptides,
some neuroanatomical prerequisites and some neurophysiolog-
ical data exist that may support some working hypothesis (Le
Mével et al., 2012). Because the peptides were injected within
the third ventricle in close proximity to the preoptic nucleus
(NPO), they can activate these preoptic neurons leading to hyper-
ventilatory and hypertensive responses through neuroendocrine
and/or neurogenic pathways. Preoptic neurons synthesize the
nonapeptides vasotocin (AVT) and isotocin (IT). AVT and IT
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FIGURE 5 | Histograms showing the maximal effects of IA injection of
50µl vehicle (n = 20), 50 pmol URP1 (n = 15) and 500pmol URP1
(n = 11), on ventilatory amplitude (VAMP, A), ventilatory frequency (fV,
B), total ventilation (VTOT, C), dorsal aortic blood pressure (PDA, D),
heart rate (fH, E), and motor activity (ACT, F). *P < 0.05 vs. vehicle
injection.
neurons project not only to the neurohypophysis, but also to
the brainstem cardiovascular and ventilatory nuclei (Batten et al.,
1990; Saito et al., 2004). It should be emphasized that in trout,
AVT produces a hypertensive response acting both centrally and
peripherally (LeMével et al., 1993). UII and URPs injected within
the third ventricle may also stimulate locomotion through the
direct or indirect projection of neurons from the NPO to mid-
brain locomotor nuclei (Lancien et al., 2004) or spinal motor
neurons as previously suggested for the control of sexual behav-
ior (Demski and Sloan, 1985; Gregory and Tweedle, 1985). In
addition, since the peptides are injected within the CSF, they
can diffuse to the mid- and hindbrain to affect motor nuclei
involved in cardio-ventilatory functions and swimming behavior
(see also 23). Interestingly, the presence of immunoreactive UII,
and URP2 gene expression, in CSF-contacting neurons in regions
surrounding notably the fourth ventricular wall, has already been
documented in various teleosts (Yulis and Lederis, 1988; Parmen-
tier et al., 2011; Quan et al., 2015), suggesting that these cells may
sense the composition of the CSF and/or release their products
within the ventricular system. Furthermore, in the eel brainstem,
the URP1 gene is detected within neurons of the commissural
nucleus of Cajal, a nucleus homologous to the nucleus tractus
solitary, the first central relay in the cardiovascular baroreflex
FIGURE 6 | Histograms showing the maximal effects of IA injection of
50µl vehicle (n = 19), 50 pmol URP2 (n = 11) and 500pmol URP2 (n = 9)
on ventilatory amplitude (VAMP, A), ventilatory frequency (fV, B), total
ventilation (VTOT, C), dorsal aortic blood pressure (PDA, D), heart rate
(fH, E), and motor activity (ACT, F).
loop (Nobata et al., 2011). Concurrently, in the zebrafish, URP1-
expressing cells are located in the reticular formation and the
glosso-pharyngeal-vagal-motor nuclei (Quan et al., 2015). Col-
lectively, our functional study and these neuroanatomical data
support a role of endogenous UII, URP1 and URP2 as neuro-
transmitters or neuromodulators involved in the central com-
mand of autonomic cardio-ventilatory and locomotor functions.
Ventilatory, Cardiovascular and Locomotor
Actions of Peripherally Administered UII, URP1,
and URP2
The peripheral actions of UII, URP1, and URP2 on cardio-
ventilatory and locomotor functionsmay be compared with those
reported in previous studies that explored the peripheral effects
of UII, URP, or URP1 in fish or in other vertebrate species but
also with their central actions. The present results on UII are
in line with our previous data obtained in trout demonstrating
that low picomole doses of UII cause a dose-dependent hyper-
tensive response and a bradycardia (Le Mével et al., 1996). In
addition, we previously investigated the cardiovascular actions
of peripherally injected trout UII (50 pmol) and hURP (50 and
500 pmol) in trout (Le Mével et al., 2008). It appears that hURP is
about ten times less potent than trout UII in evoking a hyperten-
sive response since hURP (50 pmol, about 0.2 nmol/kg) had no
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significant effect on cardiovascular variables and only the highest
dose of hURP (500 pmol, about 2 nmol/kg) produced a similar
peak increase in PDA. Furthermore, the hypertensive response
observed following the IA injection of hURP was of shorter dura-
tion than after IA injection of UII and there was no concomi-
tant bradycardia. The cardiovascular effects of UII/URPs in trout
are quite different to those obtained in eel, suggesting that the
cardiovascular actions of UII/URPs may be species dependent.
Indeed, at an equimolar dose of 0.1 nmol/kg in eel, the vaso-
pressor effects of native UII and URP1 are similar, but as for
the ICV injection, the effect of UII is longer lasting than the
action of URP1. However, in eel, both eel UII and URP1 evoke
a tachycardia (Nobata et al., 2011). In addition, after periph-
eral injections, both hUII and URP are also less potent than
the homologous peptides in eel. Thus, the results obtained with
heterologous peptides in trout and in eel, emphasize the impor-
tance of the amino-acid residues flanking the N-terminus of the
cyclic core of the fish UII-molecule in interacting with the fish
UT receptor. In trout, the hypertensive effect of UII is medi-
ated through an increase in the systemic vascular resistance since
cardiac output decreases (Le Mével et al., 1996). In mammals
including humans, a great amount of heterogeneity of vasoac-
tive responses to UII has been observed among vascular beds
from species, as well as different regions within the same species
(Douglas et al., 2000). The physiological relevance of our experi-
ments may be questioned since the concentration of the injected
peptides within the circulation might be more pharmacological
than physiological. Consequently, it remains to be determined
if physiological plasma concentration of UII may have a role in
the cardiovascular regulation in teleosts. In the present study, the
highest doses of UII and URP1 but not URP2 evoked cardio-
ventilatory and locomotor effects similar to those observed after
ICV injection of these peptides. We make the assumption that
these effects were mediated through a neurogenic pathway after
diffusion of these peptides to critical target sites in the brain that
lack the blood-brain barrier (BBB). Some neuroanatomical and
functional data favor this hypothesis. At the level of the medulla
oblongata, the area postrema is devoid of BBB and acts as a cir-
cumventricular organ in the goldfish Carassius auratus (Morita
and Finger, 1987) and in the eel Anguilla japonica (Tsukada et al.,
2007). In eel, the organum vasculosum of the lamina terminalis
is another circumventricular organ without BBB that may serve
as a window for a central action of peripherally injected regula-
tory peptides (Mukuda et al., 2013). Of interest, this latter organ
projects to the NPO. Collectively, these neuro-anatomical data in
fish and mammals are consistent with the view that circulating
UII, and eventually URP1 but not URP2, may act also as signal-
ing molecules to command some neurally-mediated regulatory
mechanisms and notably cardio-ventilatory but also locomotor
outputs.
In mammals, the UT receptor is the only high affinity receptor
for UII/URP known so far (Vaudry et al., 2015). The UT receptor
in teleosts shares about 60% identity with the human UT recep-
tor and, as previously mentioned, is strongly expressed in the
caudal neurosecretory system, the CNS and in various peripheral
tissues (Lu et al., 2006; Evans et al., 2011; Sun et al., 2014). How-
ever, recent data provide evidence for the existence of a vertebrate
ancestral UT gene that possessed five distinct UT subtypes in
teleosts (Tostivint et al., 2014). The functional role of these recep-
tor subtypes in physiological regulations is currently unknown. It
might be questioned whether the divergent physiological effects
of UII and URPs after central and peripheral injection observed
in the present study may be due to differential interaction with
the UT receptor or binding to distinct UT receptor subtypes.
In conclusion, we have examined for the first time in fish
the integrative central and peripheral physiological effects of UII,
URP1 and URP2 on cardio-ventilatory and locomotor functions.
The principal and novel findings of this study are that all peptides
produce a central stimulatory effect on ventilation, blood pres-
sure, heart rate and locomotion but with variable potency among
peptides. Since the UII, URP1, and URP2 genes are expressed
in the CNS, our results suggest that the endogenous peptides
may be implicated as neurotransmitters or neuromodulators in
the regulation of cardio-ventilatory and locomotor functions in
trout. After systemic administration of low picomole doses, none
of the UII and URP peptides affect ventilation or locomotion,
but only UII evokes hypertension and bradycardia, indicating
that endogenous UII may have a role as circulating hormone
involved in cardiovascular regulation in trout. Further studies are
clearly required to determine under which circumstances the dif-
ferent neuroendocrine and neuronal pathways that mediate the
integrative effects of the urotensinergic system are recruited to
participate in cardio-ventilatory and locomotor regulations.
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